Monobodies engineered to bind a small cleft on the SH2 domain (Fig. 3c) inhibited BCR-ABL1 kinase activity in vitro and ex vivo, and they potently induced cell death in CML cell lines. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.